Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Falcone, Colomba ^a,b,c,d   Bozzini, Sara ^a   Guasti, Luigina ^e   D'Angelo, Angela ^d   Capettini, Anna Clizia ^a   Paganini, Edoardo Maria ^b   Falcone, Rossana ^a   Moia, Roberto ^a,f   Gazzaruso, Carmine ^a,b,c   Pelissero, Gabriele ^b,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b Istituiti Clinici di Pavia e Vigevano University Hospital   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f University and Research Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

AGED; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84886534151     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/584504     Document Type: Article

References (49)

1. Congiu T., Schembri L., Tozzi M., Guasti L., Maio R. C., Cosentino M., Marino F., Scanning electron microscopy examination of endothelium morphology in human carotid plaques. Micron 2010 41 5 532 536 2-s2.0-77954387229 10.1016/j.micron.2010.01.006
2. Stehouwer C. D. A., Clement D., Davidson C., Diehm C., Elte J. W., Lambert M., Sereni D., Peripheral arterial disease: a growing problem for the internist. European Journal of Internal Medicine 2009 20 2 132 138 2-s2.0-62949128787 10.1016/j.ejim.2008.09.013
3. Sukhija R., Aronow W. S., Yalamanchili K., Sinha N., Babu S., Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. American Journal of Cardiology 2004 94 10 1358 1359 2-s2.0-7944231341 10.1016/j.amjcard.2004.07.136 (Pubitemid 39469972)
4. Dieter R. S., Tomasson J., Gudjonsson T., Brown R. L., Vitcenda M., Einerson J., McBride P. E., Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vascular Medicine 2003 8 4 233 236 2-s2.0-2342640957 10.1191/1358863x03vm506ra (Pubitemid 38585136)
5. Fung E. T., Wilson A. M., Zhang F., Harris N., Edwards K. A., Olin J. W., Cooke J. P., A biomarker panel for peripheral arterial disease. Vascular Medicine 2008 13 3 217 224 2-s2.0-58149384432 10.1177/1358863X08089276
6. Guasti L., Marino F., Cosentino M., Cimpanelli M., Maio R. C., Klersy C., Crespi C., Restelli D., Simoni C., Franzetti I., Gaudio G., Marnini P., Grandi A. M., Lecchini S., Venco A., Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. Journal of Hypertension 2006 24 12 2423 2430 2-s2.0-33750584207 10.1097/01.hjh.0000251903. 62804.77 (Pubitemid 44684691)
7. Marino F., Guasti L., Cosentino M., Rasini E., Ferrari M., Maio R. C., Loraschi A., Cimpanelli M. G., Schembri L., Legnaro M., Molteni E., Crespi C., Crema F., Venco A., Lecchini S., Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. Journal of Hypertension 2008 26 6 1147 1155 2-s2.0-43449084647 10.1097/HJH.0b013e3282f97dde (Pubitemid 351670506)
8. Guasti L., Marino F., Cosentino M., Maio R. C., Rasini E., Ferrari M., Castiglioni L., Klersy C., Gaudio G., Grandi A. M., Lecchini S., Venco A., Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-Year follow-up. European Heart Journal 2008 29 9 1118 1126 2-s2.0-45349085588 10.1093/eurheartj/ehn138 (Pubitemid 351844894)
9. Marino F., Guasti L., Cosentino M., Ferrari M., Rasini E., Maio R. C., Cimpanelli M. G., Cereda E., Crespi C., Simoni C., Restelli D., Venco A., Lecchini S., Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. Journal of Cardiovascular Pharmacology 2007 49 5 299 305 2-s2.0-34249807007 10.1097/FJC.0b013e31803d35ce (Pubitemid 46855124)
10. Marino F., Guasti L., Tozzi M., Consuelo Maio R., Castiglioni L., Rasini E., Schembri L., Maroni L., Legnaro M., De Leo A., Piffaretti G., Castelli P., Venco A., Lecchini S., Cosentino M., Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. Journal of Cardiovascular Pharmacology 2009 54 6 520 525 2-s2.0-74949105863 10.1097/FJC.0b013e3181bfadfd
11. Marino F., Maresca A. M., Cosentino M., Castiglioni L., Rasini E., Mongiardi C., Maio R. C., Legnaro M., Schembri L., Dentali F., Grandi A. M., Guasti L., Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Cardiovascular Diabetology 2012 11 article 153 10.1186/1475-2840-11-153
12. Faxon D. P., Fuster V., Libby P., Beckman J. A., Hiatt W. R., Thompson R. W., Topper J. N., Annex B. H., Rundback J. H., Fabunmi R. P., Robertson R. M., Loscalzo J., Atherosclerotic vascular disease conference. Writing group III: pathophysiology. Circulation 2004 109 21 2617 2625 2-s2.0-2642524446 10.1161/01.CIR.0000128520.37674.EF (Pubitemid 38720566)
13. Falcone C., Emanuele E., D'Angelo A., Buzzi M. P., Belvito C., Cuccia M., Geroldi D., Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 5 1032 1037 2-s2.0-18244381813 10.1161/01.ATV.0000160342.20342.00 (Pubitemid 40627851)
14. Falcone C., Buzzi M. P., Bozzini S., Boiocchi C., D'Angelo A., Schirinzi S., Choi J., Ochan Kilama M., Esposito C., Torreggiani M., Mancia G., TALENT Investigators. Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. Journal of Nephrology 2013 26 1 144 151 10.5301/jn.5000122
15. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M. P., Scioli G. A., Fogari R., Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. Journal of Hypertension 2005 23 9 1725 1729 2-s2.0-24144445082 (Pubitemid 41233433)
16. Raucci A., Cugusi S., Antonelli A., Barabino S. M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M. E., A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB Journal 2008 22 10 3716 3727 2-s2.0-54049108485 10.1096/fj.08-109033
17. Hirsch A. T., Haskal Z. J., Hertzer N. R., Bakal C. W., Creager M. A., Halperin J. L., Hiratzka L. F., Murphy W. R. C., Olin J. W., Puschett J. B., Rosenfield K. A., Sacks D., Stanley J. C., Taylor L. M. Jr., White C. J., White J., White R. A., Antman E. M., Smith S. C. Jr., Adams C. D., Anderson J. L., Faxon D. P., Fuster V., Gibbons R. J., Hunt S. A., Jacobs A. K., Nishimura R., Ornato J. P., Page R. L., Riegel B., ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology,. Circulation 2006 113 11 e463 654 2-s2.0-33645810153
18. Zeymer U., Parhofer K. G., Pittrow D., Binz C., Schwertfeger M., Limbourg T., Röther J., Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clinical Research in Cardiology 2009 98 4 249 256 2-s2.0-63449120072 10.1007/s00392-009-0754-1
19. Moussa I. D., Jaff M. R., Mehran R., Gray W., Dangas G., Lazic Z., Moses J. W., Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the peripheral arterial disease in interventional patients study. Catheterization and Cardiovascular Interventions 2009 73 6 719 724 2-s2.0-65549161533 10.1002/ccd.21969
20. Roger V. L., Go A. S., Lloyd-Jones D. M., Benjamin E. J., Berry J. D., Borden W. B., Bravata D. M., Dai S., Ford E. S., Fox C. S., Fullerton H. J., Gillespie C., Hailpern S. M., Heit J. A., Howard V. J., Kissela B. M., Kittner S. J., Lackland D. T., Lichtman J. H., Lisabeth L. D., Makuc D. M., Marcus G. M., Marelli A., Matchar D. B., Moy C. S., Mozaffarian D., Mussolino M. E., Nichol G., Paynter N. P., Soliman E. Z., Sorlie P. D., Sotoodehnia N., Turan T. N., Virani S. S., Wong N. D., Woo D., Turner M. B., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American heart association. Circulation 2012 125 1 e2 e220 2-s2.0-84855353573 10.1161/CIR.0b013e31823ac046
21. Steg G., Bhatt D. L., Wilson P. W. F., D'Agostino R. Sr., Ohman E. M., Röther J., Liau C. S., Hirsch A. T., Mas J. L., Ikeda Y., Pencina M. J., Goto S., One-year cardiovascular event rates in outpatients with atherothrombosis. Journal of the American Medical Association 2007 297 11 1197 1206 2-s2.0-33947533514 10.1001/jama.297.11.1197 (Pubitemid 46465728)
22. Brevetti G., Giugliano G., Brevetti L., Hiatt W. R., Inflammation in peripheral artery disease. Circulation 2010 122 18 1862 1875 2-s2.0-78349290032 10.1161/CIRCULATIONAHA.109.918417
23. Lindsey J. B., Cipollone F., Abdullah S. M., McGuire D. K., Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research 2009 6 1 7 14 2-s2.0-59149100896 10.3132/dvdr.2009.002
24. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Yan S. D., Hofmann M., Yan S. F., Pischetsrieder M., Stern D., Schmidt A. M., N(ε)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. Journal of Biological Chemistry 1999 274 44 31740 31749 2-s2.0-0033615356 10.1074/jbc.274.44.31740 (Pubitemid 29508546)
25. Santilli F., Vazzana N., Bucciarelli L. G., Davì G., Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Current Medicinal Chemistry 2009 16 8 940 952 2-s2.0-65649127808 10.2174/ 092986709787581888
26. Park L., Raman K. G., Lee K. J., Lu Y., Ferran L. J. Jr., Choe W. S., Stern D., Schmidt A. M., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 1998 4 9 1025 1031 2-s2.0-0031717894 10.1038/2012 (Pubitemid 28417334)
27. Goova M. T., Li J., Kislinger T., Qu W., Lu Y., Bucciarelli L. G., Nowygrod S., Wolf B. M., Caliste X., Yan S. F., Stern D. M., Schmidt A. M., Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. American Journal of Pathology 2001 159 2 513 525 2-s2.0-0034880114 (Pubitemid 32751082)
28. Taguchi A., Blood D. C., Del Toro G., Canet A., Lee D. C., Qu W., Tanjl N., Lu Y., Lalla E., Fu C., Hofmann M. A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D. M., Schmidt A. M., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000 405 6784 354 360 2-s2.0-0034682315 10.1038/35012626 (Pubitemid 30337069)
29. Kotani K., Caccavello R., Taniguchi N., Gugliucci A., Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects. Journal of International Medical Research 2012 40 1878 1883 10.1177/030006051204000527
30. Mahajan N., Malik N., Bahl A., Dhawan V., Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009 207 2 597 602 2-s2.0-70450228643 10.1016/j.atherosclerosis.2009.06.003
31. Mahajan N., Malik N., Bahl A., Sharma Y., Dhawan V., Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Molecular and Cellular Biochemistry 2009 330 1-2 201 209 2-s2.0-73349088102 10.1007/s11010-009-0134-1
32. Nakamura K., Yamagishi S. I., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., Sato A., Imaizumi T., Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes/Metabolism Research and Reviews 2007 23 5 368 371 2-s2.0-34447643578 10.1002/dmrr.690 (Pubitemid 47091239)
33. Basta G., Del Turco S., Navarra T., Mazzarisi A., Cocci F., Coceani M., Bianchi M., Schlueter M., Marraccini P., Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden. Journal of Atherosclerosis and Thrombosis 2012 19 941 948
34. Colhoun H. M., Betteridge D. J., Durrington P., Hitman G., Neil A., Livingstone S., Charlton-Menys V., Bao W., DeMicco D. A., Preston G. M., Deshmukh H., Tan K., Fuller J. H., Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011 60 9 2379 2385 2-s2.0-80052885987 10.2337/db11-0291
35. Nin J. W. M., Jorsal A., Ferreira I., Schalkwijk C. G., Prins M. H., Parving H. H., Tarnow L., Rossing P., Stehouwer C. D. A., Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010 59 8 2027 2032 2-s2.0-77955347413 10.2337/db09-1509
36. Fujisawa K., Katakami N., Kaneto H., Naka T., Takahara M., Sakamoto F., Irie Y., Miyashita K., Kubo F., Yasuda T., Matsuoka T. A., Shimomura I., Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013 227 425 428 10.1016/j.atherosclerosis.2013.01.016
37. Chiang K. H., Huang P. H., Huang S. S., Wu T. C., Chen J. W., Lin S. J., Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coronary Artery Disease 2009 20 4 267 273 2-s2.0-67649668763 10.1097/MCA.0b013e32832c459c
38. Selvin E., Halushka M., Rawlings A., Hoogeveen R. C., Ballantyne C. M., Coresh J., Astor B. C., sRAGE and risk of diabetes, cardiovascular disease and death. Diabetes 2013 62 6 2116 2121 10.2337/db12-1528
39. McNair E. D., Wells C. R., Mabood Qureshi A., Basran R., Pearce C., Orvold J., Devilliers J., Prasad K., Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clinical Cardiology 2010 33 11 678 685 2-s2.0-78649639285 10.1002/clc.20815
40. Fukushima Y., Daida H., Morimoto T., Kasai T., Miyauchi K., Yamagishi S., Takeuchi M., Hiro T., Kimura T., Nakagawa Y., Yamagishi M., Ozaki Y., Matsuzaki M., JAPAN-ACS Investigators. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovascular Diabetology 2013 12 article 5 10.1186/1475-2840-12-5
41. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., Emoto M., Shoji T., Tamei H., Matsuki H., Sakurai S., Yamamoto Y., Yonekura H., Watanabe T., Yamamoto H., Nishizawa Y., Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 12 2587 2593 2-s2.0-33644808985 10.1161/01.ATV.0000190660.32863.cd (Pubitemid 43732283)
42. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T. A., Sakamoto K., Nakatani Y., Ohtoshi K., Hayaishi-Okano R., Kosugi K., Hori M., Yamasaki Y., Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005 28 11 2716 2721 2-s2.0-32844466467 10.2337/diacare.28.11.2716 (Pubitemid 43951165)
43. Basta G., Sironi A. M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., Gastaldelli A., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. Journal of Clinical Endocrinology and Metabolism 2006 91 11 4628 4634 2-s2.0-33751509416 10.1210/jc.2005-2559 (Pubitemid 44833448)
44. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., Clissa C., Ciabattoni G., Consoli A., Davì G., Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radical Biology and Medicine 2007 43 4 511 518 2-s2.0-34447331279 10.1016/j.freeradbiomed.2007.03. 015 (Pubitemid 47058227)
45. Challier M., Jacqueminet S., Benabdesselam O., Grimaldi A., Beaudeux J. L., Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clinical Chemistry 2005 51 9 1749 1750 2-s2.0-24144459068 10.1373/clinchem.2005.051961 (Pubitemid 41233122)
46. Tan K. C., Shiu S. W., Chow W. S., Leng L., Bucala R., Betteridge D. J., Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006 49 11 2756 2762 2-s2.0-33947408459 10.1007/s00125-006-0394-1
47. McNair E. D., Wells C. R., Mabood Qureshi A., Basran R., Pearce C., Orvold J., Devilliers J., Prasad K., Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Molecular and Cellular Biochemistry 2010 341 1-2 135 138 2-s2.0-77955013993 10.1007/s11010-010-0444-3
48. Kinlay S., Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. A meta-analysis. Journal of the American College of Cardiology 2007 49 20 2003 2009 2-s2.0-34248342266 10.1016/j.jacc.2007.01.083 (Pubitemid 46734641)
49. Yonekura H., Yamamoto Y., Sakurai S., Petrova R. G., Abedin M. J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., Yamamoto H., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal 2003 370 3 1097 1109 2-s2.0-0037444761 10.1042/BJ20021371 (Pubitemid 36399105)